OOIR: Observatory of International Research

Papers

(The median citation count of Frontiers in Oncology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis	248
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future	232
EMT Factors and Metabolic Pathways in Cancer	195
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers	186
Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond	166
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics	161
Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression	152
Mechanisms of Cancer Resistance to Immunotherapy	149
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy	148
Chronic Stress Promotes Cancer Development	148
The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity	147
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology	142
Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers	140
Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways	131
Integrated Multi-Omics Analyses in Oncology: A Review of Machine Learning Methods and Tools	129
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions	126
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors	124
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?	121
The Multidisciplinary Team (MDT) Approach and Quality of Care	121
Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis	120
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis	116
Metabolic Reprogramming in Triple-Negative Breast Cancer	116
Breast Cancer Survivorship, Quality of Life, and Late Toxicities	115
Boron Neutron Capture Therapy: A Review of Clinical Applications	114
Mutant p53 in Cancer Progression and Targeted Therapies	113

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy	112
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation	112
The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy	112
Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming	111
Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma	108
Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors	107
Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups	107
Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data	106
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches	104
Metabolic Plasticity in Chemotherapy Resistance	103
Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment	102
Metabolic Adaptations in Cancer Stem Cells	99
P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers	99
Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship	95
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells	94
Integrated Analysis of lncRNA–Mediated ceRNA Network in Lung Adenocarcinoma	93
Clinical and Biological Significances of a Ferroptosis-Related Gene Signature in Glioma	93
Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment	92
Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib	92
Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer	92
Artificial Convolutional Neural Network in Object Detection and Semantic Segmentation for Medical Imaging Analysis	92
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects	91
The role of BCL-2 family proteins in regulating apoptosis and cancer therapy	90
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model	90
Proline Metabolism in Tumor Growth and Metastatic Progression	88
Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy	88
Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade	87
Psychological Distress in Outpatients With Lymphoma During the COVID-19 Pandemic	87
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies	87
An Emerging Class of Long Non-coding RNA With Oncogenic Role Arises From the snoRNA Host Genes	86
Sexual Dimorphism in Colon Cancer	85
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment	85
Shaping Up the Tumor Microenvironment With Cellular Fibronectin	85
Has COVID-19 Affected Cancer Screening Programs? A Systematic Review	84
A Review on Anti-Tumor Mechanisms of Coumarins	84
Delivery and Biosafety of Oncolytic Virotherapy	83
Perplexing Role of P-Glycoprotein in Tumor Microenvironment	82
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?	82
Ferroptosis in Cancer Treatment: Another Way to Rome	82
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma	82
Emerging Roles of Wnt Ligands in Human Colorectal Cancer	81
Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy	81
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism	81
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation	80
Obesity, Type 2 Diabetes, and Cancer Risk	80
The Role of the Transcription Factor EGR1 in Cancer	80
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients	80
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies	79
BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining	79
Global Research Trends on Prostate Diseases and Erectile Dysfunction: A Bibliometric and Visualized Study	78

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy	78
Knowledge Domain and Emerging Trends in Ferroptosis Research: A Bibliometric and Knowledge-Map Analysis	78
Role of DNA Methylation in the Resistance to Therapy in Solid Tumors	76
Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk	76
New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma	75
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review	75
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion	75
Immune Checkpoint Inhibitors in the Treatment of HCC	74
A Novel Prognostic Marker Systemic Inflammation Response Index (SIRI) for Operable Cervical Cancer Patients	74
Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases	73
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)	72
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies	71
Sintilimab: A Promising Anti-Tumor PD-1 Antibody	71
Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters	71
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease	71
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy	71
Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications	70
The Oncolytic Virus in Cancer Diagnosis and Treatment	70
Lactate Modulates Cellular Metabolism Through Histone Lactylation-Mediated Gene Expression in Non-Small Cell Lung Cancer	69
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment	69
EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives	68
A Review of Newly Diagnosed Glioblastoma	68
m6A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1	68
Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer	68
Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer	68
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review	67
An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma	67
Cysteine Depletion, a Key Action to Challenge Cancer Cells to Ferroptotic Cell Death	67
FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis	67
Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology	66
Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status	66
MYCN Function in Neuroblastoma Development	66
The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer	66
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer	66
Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review	65
Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting	65
Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease	65
Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment	65
RNA-Seq Profiling of Serum Exosomal Circular RNAs Reveals Circ-PNN as a Potential Biomarker for Human Colorectal Cancer	65
Humanized Rodent Models for Cancer Research	65
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer	65
Cancer in Africa: The Untold Story	65
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment	64
Systemic Reprogramming of Monocytes in Cancer	64
Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine	63
Osteosarcoma and Metastasis	63
CAR-NK Cell: A New Paradigm in Tumor Immunotherapy	63
YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy	63
Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance	62
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer	62
Meningioma: A Review of Clinicopathological and Molecular Aspects	62
The Metabolic Mechanisms of Breast Cancer Metastasis	61
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents	61
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics	61
The Mevalonate Pathway, a Metabolic Target in Cancer Therapy	61
Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma	60
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions	60
Targeted Therapies and Biomarkers in Small Cell Lung Cancer	60
Genome-Wide Sex and Gender Differences in Cancer	60
Immunotherapy in Acute Myeloid Leukemia: Where We Stand	60
The Landscape of Immune Cells Infiltrating in Prostate Cancer	60
Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma	59
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment	59
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences	59
Pyroptosis-Related Gene Signatures Can Robustly Diagnose Skin Cutaneous Melanoma and Predict the Prognosis	59
A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis	59
Computational Oncology in the Multi-Omics Era: State of the Art	58
Reciprocal Interplay Between Fibrillar Collagens and Collagen-Binding Integrins: Implications in Cancer Progression and Metastasis	58
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer	58
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review	58
Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy	57
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives	57
LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer	57
Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk	57
m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma	57
The Interaction Between lncRNA SNHG6 and hnRNPA1 Contributes to the Growth of Colorectal Cancer by Enhancing Aerobic Glycolysis Through the Regulation of Alternative Splicing of PKM	56
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy	56
Artificial Intelligence (AI)-Based Systems Biology Approaches in Multi-Omics Data Analysis of Cancer	56
A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations	56
FLASH Radiotherapy: History and Future	56

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy	55
LncRNA-Encoded Peptide: Functions and Predicting Methods	55
Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells	55
The Role of Iron in Cancer Progression	55
Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers	55
Targeting CXCR4 in AML and ALL	55
The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology	55
Probiotics in Cancer	55
Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma	55
Induction of Pyroptosis: A Promising Strategy for Cancer Treatment	54
Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer	54
The Role of CD276 in Cancers	54
Inhibition of Fatty Acid Synthase Upregulates Expression of CD36 to Sustain Proliferation of Colorectal Cancer Cells	54
5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent	54
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy	54
68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma	54
Extracellular Matrix Stiffness: New Areas Affecting Cell Metabolism	54
Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?	54
Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?	53
Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor	53
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors	53
Primary Cutaneous B-Cell Lymphomas: An Update	53
The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017	53
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma	53
MR-Guided Radiotherapy for Prostate Cancer	53
VCAM1 Promotes Tumor Cell Invasion and Metastasis by Inducing EMT and Transendothelial Migration in Colorectal Cancer	52
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications	52
Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy	52
Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine	52
The Lipid Metabolic Landscape of Cancers and New Therapeutic Perspectives	52
Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer	52
Patient-Derived Cancer Organoids as Predictors of Treatment Response	52
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank	52
Identification of Hub Genes Associated With Development of Head and Neck Squamous Cell Carcinoma by Integrated Bioinformatics Analysis	51
Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma	51
Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments	51
Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer	51
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy	51
The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development	51
The role of IL-6/JAK2/STAT3 signaling pathway in cancers	51
Starting a Fire Without Flame: The Induction of Cell Death and Inflammation in Electroporation-Based Tumor Ablation Strategies	51
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma	51
Platelets and Metastasis: New Implications of an Old Interplay	51
Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis	51
Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options	50
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia	50
Actors on the Scene: Immune Cells in the Myeloma Niche	50
Acetyl-CoA Carboxylases and Diseases	50
PPAR-α Modulators as Current and Potential Cancer Treatments	50
A Review on Application of Deep Learning Algorithms in External Beam Radiotherapy Automated Treatment Planning	50
Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance—A Mini Review	50
GLI1: A Therapeutic Target for Cancer	49
Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study	49
Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer	49
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?	49
The Endosteal Niche in Breast Cancer Bone Metastasis	49
Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)	49
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer	49
Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues	49
A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma	49
Emerging Role of Circular RNAs in Cancer	49
Radiation Resistance: A Matter of Transcription Factors	49
PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis	48
More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?	48
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade	48
An Original Ferroptosis-Related Gene Signature Effectively Predicts the Prognosis and Clinical Status for Colorectal Cancer Patients	48
Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma	48
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer	48
CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment	48
High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes	47
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies	47
The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer	47
The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis	47
Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis	47
Application of a 3D Bioprinted Hepatocellular Carcinoma Cell Model in Antitumor Drug Research	47
Long Non-coding RNA MEG3 Activated by Vitamin D Suppresses Glycolysis in Colorectal Cancer via Promoting c-Myc Degradation	47
m6A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis	47
Understanding Sources of Variation to Improve the Reproducibility of Radiomics	47
PI(3,4)P2 Signaling in Cancer and Metabolism	47
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities	47
Dysbiosis of Oral Microbiota During Oral Squamous Cell Carcinoma Development	47
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade	47
Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses	47
The Role of Non-Coding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells	47
Review on the Cellular Mechanisms of Low-Level Laser Therapy Use in Oncology	46
The Role of the ECM in Lung Cancer Dormancy and Outgrowth	46
Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model	46
Proteomic Profiling of Serum Exosomes From Patients With Metastatic Gastric Cancer	46
The Implications of PDK1–4 on Tumor Energy Metabolism, Aggressiveness and Therapy Resistance	46
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?	46
A Deep Multi-Task Learning Framework for Brain Tumor Segmentation	46
Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma	46
Sirt4: A Multifaceted Enzyme at the Crossroads of Mitochondrial Metabolism and Cancer	46
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer	46
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions	45